REG - Immupharma PLC - Result of AGM

ImmuPharmaAnnouncement

30/06/2023 13:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230630:nRSd5929Ea&default-theme=true

RNS Number : 5929E  Immupharma PLC  30 June 2023

 

 

RNS:
RELEASE
30 June 2023

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

2023 RESULT OF ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, held its AGM earlier today. The Company is pleased to announce that
all resolutions were duly passed, details of which are contained in the table
below.

 

 

 Resolution                                                                       For          % For  Against    % Against  Withheld
 1. To receive the accounts of the Company for the year ended 31 December 2022    52,114,317   99.08  482,400    0.92       49,317
 together with the reports thereon of the directors and auditors of the Company

 2. To re-appoint Dr Sanjeev Pandya as a director of the Company                  47,601,452   90.55  4,964,842  9.44       79,740

 3. To re-appoint CLA Evelyn Partners Limited as Auditor of the Company           52,084,178   99.08  482,400    0.92       79,456

 4. That the Directors be authorised for the purpose of Section 551 of the        51,003,388   98.86  585,640    1.14       1,057,006
 Companies Act 2006 (the "Act") to allot shares on the basis as set out in the

 Notice of Meeting
 5.    That the Company may send or supply documents or information to                         99.08  484,400    0.92       46,417
 members by making them available on a website or other electronic means.

                                                                                  52,115,217

 SPECIAL RESOLUTION                                                               51,013,053   99.88  575,975    1.12       1,057,006

 6.    That, subject to the passing of Resolution 4 the directors be and
 they are hereby empowered pursuant to section 571 of the Act to allot equity
 securities (as defined in section 560 of the Act).

 

 

As at the date of the AGM, the number of issued ordinary shares of the Company
was 333,403,115 shares, which was the total number of shares entitling the
holders to attend and vote for or against all resolutions. In accordance with
the Company's Articles of Association, every member has one vote for every
share held. Votes withheld are not votes in law and have not been counted in
the calculation of the proportion of vote "for" or "against" a
resolution. Proxy appointments which gave discretion to the Chairman have
been included in the "for" total.

 

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation no 596/2014 which is part of English
law by virtue of the European (withdrawal) Act 2018, as amended.  On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

Ends

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )        +44 (0) 207 206 2650

 Tim McCarthy, Chairman and Chief Executive Officer
 Lisa Baderoon, Head of Investor Relations & Non-Executive Director      + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                                 +44 (0) 203 368 3550 (about:blank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                                +44 (0) 20 3650 3650

 Patrick Claridge, John Howes, Bob Pountney

 SI Capital (Joint Broker)                                               +44 (0) 1483 413500

 Nick Emerson

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class
autophagy immunomodulator for the treatment of Lupus and preclinical analysis
suggest therapeutic activity for many other autoimmune diseases that share the
same autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma
(http://www.immupharma) .co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGMZGFVZGMGFZM